Jane Street’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.04M Sell
106,400
-85,200
-44% -$3.78M ﹤0.01% 3442
2026
Q1
$5.69M Sell
191,600
-65,200
-25% -$1.95M ﹤0.01% 3318
2025
Q4
$9.81M Sell
256,800
-65,400
-20% -$2.13M ﹤0.01% 2342
2025
Q3
$7.7M Sell
322,200
-164,000
-34% -$3.08M ﹤0.01% 2772
2025
Q2
$7.2M Buy
486,200
+281,200
+137% +$4.66M ﹤0.01% 2543
2025
Q1
$3.67M Sell
205,000
-57,300
-22% -$1.16M ﹤0.01% 3391
2024
Q4
$4.57M Buy
262,300
+166,400
+174% +$2.94M ﹤0.01% 2791
2024
Q3
$1.34M Buy
95,900
+85,600
+831% +$892K ﹤0.01% 5283
2024
Q2
$84.7K Sell
10,300
-200
-2% -$1.35K ﹤0.01% 8791
2024
Q1
$81K Sell
10,500
-32,800
-76% -$277K ﹤0.01% 8605
2023
Q4
$389K Sell
43,300
-13,900
-24% -$101K ﹤0.01% 7205
2023
Q3
$511K Buy
57,200
+31,800
+125% +$449K ﹤0.01% 6265
2023
Q2
$390K Buy
+25,400
New +$462K ﹤0.01% 6693
2022
Q3
Sell
-15,600
Closed -$378K 10491
2022
Q2
$378K Sell
15,600
-26,200
-63% -$659K ﹤0.01% 7218
2022
Q1
$1.08M Buy
41,800
+19,700
+89% +$523K ﹤0.01% 5982
2021
Q4
$686K Buy
+22,100
New +$622K ﹤0.01% 6678
2015
Q3
Sell
-9,500
Closed -$315K 4158
2015
Q2
$315K Buy
+9,500
New +$260K ﹤0.01% 2769

Other funds holding TVTX

Jane Street's TVTX Position: Q2 2026 in Review

Jane Street increased its Travere Therapeutics (TVTX) stake by 211% in Q2 2026, buying an estimated $28.2M and bringing the position to 938,699 shares worth $53.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1371.

Jane Street first reported a position in TVTX in Q1 2014 and has held it in 26 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Jane Street held 938,699 shares of Travere Therapeutics worth $53.3M as of Q2 2026.
  • Jane Street bought 636,419 Travere Therapeutics shares in Q2 2026, an estimated $28.2M.
  • Travere Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #1371 holding.
  • Jane Street first reported a position in Travere Therapeutics in Q1 2014 and has held it in 26 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.